Positive health outcomes in trial of LY 2189265 for T2D

Eli Lilly has announced positive patient-reported health outcomes from a Phase III clinical trial of LY 2189265 (dulaglutide), as a once-weekly treatment for Type 2 Diabetes. Dulaglutide-treated patients reported significant, positive improvements compared to baseline across several patient-reported indicators of diabetes management, measured using validated questionnaires.

The patient-reported outcomes from the AWARD-1 trial showed that treatment satisfaction, as measured by the DTSQ, was significantly higher with dulaglutide compared to baseline, and was significantly greater compared to placebo and exenatide twice-daily at 26 weeks. Clinical results showed that treatment with dulaglutide 1.5 mg led to improvements in HbA1c levels and weight reductions. These results will be presented at the 49th European Association for the Study of Diabetes.